Lotus Eye Hospital and Institute Résultats passés
Passé contrôle des critères 2/6
Lotus Eye Hospital and Institute has been growing earnings at an average annual rate of 26.8%, while the Healthcare industry saw earnings growing at 29.2% annually. Revenues have been growing at an average rate of 7% per year. Lotus Eye Hospital and Institute's return on equity is 3.6%, and it has net margins of 4.4%.
Informations clés
26.8%
Taux de croissance des bénéfices
27.2%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 29.4% |
| Taux de croissance des recettes | 7.0% |
| Rendement des fonds propres | 3.6% |
| Marge nette | 4.4% |
| Prochaine mise à jour des résultats | 12 Nov 2024 |
Mises à jour récentes des performances passées
Recent updates
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking
Aug 21
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings
Jan 24Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 08We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Jul 15Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors
Apr 07We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Oct 08Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 02If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity
Jun 17MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Mar 11Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Dec 30Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares
Nov 20The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares
Sep 21Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E
Aug 27
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?
Aug 03Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises
Jul 06Ventilation des recettes et des dépenses
Comment Lotus Eye Hospital and Institute gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 485 | 22 | 35 | 0 |
| 31 Mar 24 | 482 | 29 | 35 | 0 |
| 31 Dec 23 | 485 | 35 | 34 | 0 |
| 30 Sep 23 | 486 | 40 | 34 | 0 |
| 30 Jun 23 | 477 | 41 | 0 | 0 |
| 31 Mar 23 | 470 | 41 | 34 | 0 |
| 31 Dec 22 | 464 | 40 | 31 | 0 |
| 30 Sep 22 | 459 | 42 | 31 | 0 |
| 30 Jun 22 | 449 | 46 | 0 | 0 |
| 31 Mar 22 | 389 | 30 | 32 | 0 |
| 31 Dec 21 | 389 | 36 | 23 | 0 |
| 30 Sep 21 | 372 | 32 | 23 | 0 |
| 30 Jun 21 | 335 | 20 | 0 | 0 |
| 31 Mar 21 | 324 | 16 | 23 | 0 |
| 31 Dec 20 | 300 | -5 | 36 | 0 |
| 30 Sep 20 | 301 | -14 | 36 | 0 |
| 30 Jun 20 | 335 | -6 | 0 | 0 |
| 31 Mar 20 | 406 | 11 | 36 | 0 |
| 31 Dec 19 | 420 | 21 | 30 | 0 |
| 30 Sep 19 | 415 | 20 | 30 | 0 |
| 30 Jun 19 | 401 | 11 | 0 | 0 |
| 31 Mar 19 | 384 | 7 | 35 | 0 |
| 31 Dec 18 | 382 | 7 | 32 | 0 |
| 30 Sep 18 | 381 | 9 | 32 | 0 |
| 30 Jun 18 | 384 | 14 | 0 | 0 |
| 31 Mar 18 | 380 | 17 | 31 | 0 |
| 31 Dec 17 | 373 | 8 | 29 | 0 |
| 30 Sep 17 | 359 | 4 | 29 | 0 |
| 30 Jun 17 | 350 | 6 | 0 | 0 |
| 31 Mar 17 | 340 | 4 | 29 | 0 |
| 31 Dec 16 | 330 | 7 | 27 | 0 |
| 30 Sep 16 | 324 | 7 | 27 | 0 |
| 30 Jun 16 | 314 | 0 | 0 | 0 |
| 31 Mar 16 | 311 | 1 | 27 | 0 |
| 31 Dec 15 | 311 | -5 | 51 | 0 |
| 30 Sep 15 | 315 | -6 | 51 | 0 |
| 30 Jun 15 | 308 | -14 | 51 | 0 |
| 31 Mar 15 | 302 | -20 | 31 | 0 |
| 31 Dec 14 | 298 | -12 | 41 | 0 |
| 30 Sep 14 | 290 | -9 | 41 | 0 |
| 30 Jun 14 | 289 | 1 | 41 | 0 |
| 31 Mar 14 | 288 | 0 | 41 | 0 |
| 31 Dec 13 | 287 | 4 | 37 | 0 |
Des revenus de qualité: LOTUSEYE has high quality earnings.
Augmentation de la marge bénéficiaire: LOTUSEYE's current net profit margins (4.4%) are lower than last year (8.6%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: LOTUSEYE's earnings have grown significantly by 26.8% per year over the past 5 years.
Accélération de la croissance: LOTUSEYE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: LOTUSEYE had negative earnings growth (-47.3%) over the past year, making it difficult to compare to the Healthcare industry average (30.6%).
Rendement des fonds propres
ROE élevé: LOTUSEYE's Return on Equity (3.6%) is considered low.